Aerie Pharmaceuticals Logo

News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals Announces New Employee Inducement Grant
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 15, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Second Quarter Glaucoma Franchise Net Revenues of $33.3 Million , up 23% over Second Quarter 2021 Outlook for Net Cash Used Expected to Be Less Than $20 Million per Quarter, on Average, for the Remainder of 2022   Aerie Expects to be Cash Flow Break Even During 2024 DURHAM, N.C.DURHAM ,
View HTML
Toggle Summary Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease
AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye Disease COMET-3 is the second of three studies in the AR-15512 Registrational Phase 3 Program DURHAM, N.C. --(BUSINESS WIRE)--Aug. 1, 2022-- Aerie Pharmaceuticals, Inc.
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 28, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after
View HTML
Toggle Summary Aerie Pharmaceuticals Announces New Employee Inducement Grant
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 8, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
DURHAM, N.C. --(BUSINESS WIRE)--May 25, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan , Chief Executive Officer, along with Peter Lang ,
View HTML
Toggle Summary Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye Disease COMET-2 is the first of three studies in the AR-15512 Phase 3 Program DURHAM, N.C. --(BUSINESS WIRE)--May 24, 2022-- Aerie Pharmaceuticals, Inc.
View HTML
Toggle Summary Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
First Quarter Glaucoma Franchise Net Revenues of $29.8 Million , up 30% over First Quarter 2021 Management Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 Million First Phase 3 Registrational Trial for AR-15512 On-Track for Enrollment Second Quarter of 2022 DURHAM, N.C.
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 28, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present first quarter 2022 financial results after
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022
Abstracts showcase Rhopressa ® / netarsudil, AR-15512 and “ROCK’Ster” DURHAM, N.C. --(BUSINESS WIRE)--Apr. 26, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today
View HTML
TOP